Recent developments in CCR2 antagonists

@article{Xia2009RecentDI,
  title={Recent developments in CCR2 antagonists},
  author={Mingde Xia and Zhihua Flemington Sui},
  journal={Expert Opinion on Therapeutic Patents},
  year={2009},
  volume={19},
  pages={295 - 303}
}
  • Mingde Xia, Z. Sui
  • Published 1 March 2009
  • Biology, Medicine
  • Expert Opinion on Therapeutic Patents
Monocyte chemoattractant protein-1 (MCP-1) is a major chemoattractant for monocytes and memory T cells by means of their binding to its specific cell-surface receptor, CC-chemokine receptor-2 (CCR2). CCR2 belongs to the G-protein-coupled seven-transmembrane receptor superfamily. The evidence in favor of CCR2 and MCP-1 having dominant roles in monocyte chemotaxis and chronic inflammation was provided by CCR2 and MCP-1 knockout mice. It has been recognized that CCR2 antagonists are potential… 
Role of chemokine CCL2 and its receptor CCR2 in neurodegenerative diseases
TLDR
The present review will focus on the biological and pathophysiological aspects of CCL2 and CCR2 in the CNS and the possible therapeutic approaches for targeting these two proteins to combat neurodegenerative diseases.
Novel C-C chemokine receptor 2 antagonists in metabolic disease: a review of recent developments
TLDR
This review focuses on the roles of CCR2 in the pathogenesis of adipose tissue inflammation and other organ damage associated with metabolic syndrome, which is still a matter of debate in many studies, and the use of novel C CR2 antagonists as therapies in such conditions.
The Role of MCP-1(Monocyte Chemoattractant Protein-1) in Restenosis
TLDR
The available resources of database are used to discuss in detail about the clinical significances, the signaling pathways in which MCP-1 play a role, gene polymorphism and its effects, the role of M CP-1 in vascular disease, particularly the role in the artery reclogging and finally the gene therapy mediated by MCP -1- inhibition on restenosis.
High-Content Analysis of CCR2 Antagonists on Human Primary Monocytes
TLDR
Analysis of MCP-1 internalization into primary human monocytes raises the distinct possibility that some CCR2 antagonists are capable of discriminating between different functional states of the C CR2 receptor(s) and suggest strategies for the identification of functionally selective CCR1 antagonists with increased therapeutic advantage over nonselective antagonists.
Selective and Dual Targeting of CCR2 and CCR5 Receptors: A Current Overview
TLDR
The fact that CCR2 and CCR5 receptor antagonists contribute to the treatment of inflammatory diseases renders the development of dual antagonists as promising novel therapeutic strategy.
Role of CCR2 in immunobiology and neurobiology
TLDR
The present review emphasizes CCR2/CCL2 as a key chemokine/chemokine receptor pair that controls the recruitment or retention of a key subset of mononuclear phagocytes in inflammation associated with host defense or disease.
The molecular structure and role of CCL2 (MCP‐1) and C‐C chemokine receptor CCR2 in skeletal biology and diseases
TLDR
Understanding the role of CCL2 and CCR2 will facilitate the development of novel therapies for skeletal disorders, including rheumatoid arthritis, osteolysis and other inflammatory diseases related to abnormal chemotaxis.
Progress in the discovery of CC chemokine receptor 2 antagonists, 2009 – 2012
  • P. Carter
  • Biology, Medicine
    Expert opinion on therapeutic patents
  • 2013
TLDR
Significant progress continues to be made in identifying novel, potent CCR2 antagonists and researchers have had success in addressing issues related to selectivity, cardiac safety, and preclinical pharmacokinetics.
Targeting the CCL2/CCR2 Axis in Cancer Immunotherapy: One Stone, Three Birds?
TLDR
It is presented here that beneficial effects of CCR2 antagonism in the tumor setting extend beyond blocking chemotaxis of suppressive myeloid cells and the CCL2/CCR2 axis directly contributes to survival/growth and invasion/metastasis of many types of tumors bearing C CR2.
Spiroindenes and spiroindanes as antagonists of CC chemokine receptor 2: WO 2009023754
  • P. Carter
  • Medicine, Biology
    Expert opinion on therapeutic patents
  • 2010
TLDR
The compounds disclosed in PCT application WO 2009023754 extend previous work in a dipiperidine series of CCR2 antagonists through the introduction of both a 1,2-disubstituted ethanol spacer and a 1′H-spiro[indene-1,4′-piperin]-1′-yl group, which may represent a means of treating diseases driven by C CR2-bearing leukocytes.
...
...

References

SHOWING 1-10 OF 27 REFERENCES
Monocyte chemoattractant protein 1: a potential regulator of monocyte recruitment in inflammatory disease.
  • B. Rollins
  • Biology, Medicine
    Molecular medicine today
  • 1996
Targeting monocyte chemoattractant protein-1 signalling in disease
TLDR
Experimental evidence for a detrimental role of MCP-1 in stroke and excitotoxic injury has been found and the proof for the validity of targeting M CP-1 signalling in disease has yet to be established in clinical trials.
Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosis
TLDR
A role for MCP-1 in the development of early atherosclerotic lesions is revealed and upregulation of this chemokine by minimally oxidized lipids is an important link between hyperlipidaemia and fatty streak formation.
Blockade of CCR2 ameliorates progressive fibrosis in kidney.
Unusual Chemokine Receptor Antagonism Involving a Mitogen-Activated Protein Kinase Pathway1
TLDR
This report provides direct evidence for a novel mechanism how chemokine receptor function can be arrested by endogenous ligands and shows that binding of eotaxin to CCR2 stimulates the mitogen-activated protein kinases extracellular signal-regulated kinase 1/2 (ERK1/2).
Chemokines in the pathogenesis of vascular disease.
TLDR
Roles of the chemokines, a family of small secreted proteins that selectively recruit monocytes, neutrophils, and lymphocytes to sites of vascular injury, inflammation, and developing atherosclerosis, are summarized.
Leishmania-Derived Murine Monocyte Chemoattractant Protein 1 Enhances the Recruitment of a Restrictive Population of CC Chemokine Receptor 2-Positive Macrophages
TLDR
This work suggests that the parasite-derived MCP-1 can recruit a restrictive population of CCR2-positive macrophages into lesions that can be optimally stimulated by M CP-1 and IFN-γ to efficiently kill Leishmania parasites.
Discovery and Pharmacological Characterization of a Novel Rodent-Active CCR2 Antagonist, INCB3344
TLDR
It is demonstrated that therapeutic dosing of INCB3344 significantly reduces disease in mice subjected to experimental autoimmune encephalomyelitis, a model of multiple sclerosis, as well as a rat model of inflammatory arthritis, which support targeting this receptor for the treatment of chronic inflammatory diseases.
CCR2 modulates inflammatory and metabolic effects of high-fat feeding.
TLDR
The data suggest that CCR2 influences the development of obesity and associated adipose tissue inflammation and systemic insulin resistance and plays a role in the maintenance of adipOSE tissue macrophages and insulin resistance once obesity and its metabolic consequences are established.
Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibroblast differentiation.
TLDR
It is shown that CCR2 is up-regulated in early dcSSc on cell types known to be activated in the disease, which is consistent with a key role in SSc pathogenesis.
...
...